1. |
Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal Reflux Disease. JAMA, 2020, 324(24): 2565.
|
2. |
Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut, 2018, 67(3): 430-440.
|
3. |
Nirwan JS, Hasan SS, Babar ZU, et al. Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): systematic review with meta-analysis. Sci Rep, 2020, 10(1): 5814.
|
4. |
Fass R. Gastroesophageal reflux disease. N Engl J Med, 2022, 387(13): 1207-1216.
|
5. |
Zheng Z, Shang Y, Wang N, et al. Current advancement on the dynamic mechanism of gastroesophageal reflux disease. Int J Biol Sci, 2021, 17(15): 4154-4164.
|
6. |
Gillespie MR, Rai V, Agrawal S, et al. The role of microbiota in the pathogenesis of esophageal adenocarcinoma. Biology (Basel), 2021, 10(8): 697.
|
7. |
Zhou J, Shrestha P, Qiu Z, et al. Distinct microbiota dysbiosis in patients with non-erosive reflux disease and esophageal adenocarcinoma. J Clin Med, 2020, 9(7): 2162.
|
8. |
Sugihartono T, Fauzia KA, Miftahussurur M, et al. Analysis of gastric microbiota and Helicobacter pylori infection in gastroesophageal reflux disease. Gut Pathog, 2022, 14(1): 38.
|
9. |
Gao L, Xu T, Huang G, et al. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell, 2018, 9(5): 488-500.
|
10. |
Lee YH, Chung SW, Auh QS, et al. Progress in oral microbiome related to oral and systemic diseases: an update. Diagnostics (Basel), 2021, 11(7): 1283.
|
11. |
Kawar N, Park SG, Schwartz JL, et al. Salivary microbiome with gastroesophageal reflux disease and treatment. Sci Rep, 2021, 11(1): 188.
|
12. |
Ziganshina EE, Sagitov II, Akhmetova RF, et al. Comparison of the microbiota and inorganic anion content in the saliva of patients with gastroesophageal reflux disease and gastroesophageal reflux disease-free individuals. Biomed Res Int, 2020, 2020: 2681791.
|
13. |
Koeda M, Tanabe T, Kitasako Y, et al. Saliva secretion is reduced in proton pump inhibitor-responsive non-erosive reflux disease patients. Esophagus, 2021, 18(4): 900-907.
|
14. |
Nascimento MM. Approaches to modulate biofilm ecology. Dent Clin North Am, 2019, 63(4): 581-594.
|
15. |
Wang YJ, Lang XQ, Wu D, et al. Salivary pepsin as an intrinsic marker for diagnosis of sub-types of gastroesophageal reflux disease and gastroesophageal reflux disease-related disorders. J Neurogastroenterol Motil, 2020, 26(1): 74-84.
|
16. |
蒋兴宇, 赵霞, 邹凌云, 等. 适度运动对人体肠道菌群结构的影响. 第三军医大学学报, 2017, 39(18): 1824-1831.
|
17. |
Pignatelli P, Fabietti G, Ricci A, et al. How periodontal disease and presence of nitric oxide reducing oral bacteria can affect blood pressure. Int J Mol Sci, 2020, 21(20): 7538.
|
18. |
Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res, 2012, 18(8): 2138-2144.
|
19. |
Snider EJ, Compres G, Freedberg DE, et al. Barrett’s esophagus is associated with a distinct oral microbiome. Clin Transl Gastroenterol, 2018, 9(3): 135.
|
20. |
Nardone G, Compare D, Rocco A. A microbiota-centric view of diseases of the upper gastrointestinal tract. Lancet Gastroenterol Hepatol, 2017, 2(4): 298-312.
|
21. |
D’Souza SM, Houston K, Keenan L, et al. Role of microbial dysbiosis in the pathogenesis of esophageal mucosal disease: a paradigm shift from acid to bacteria?. World J Gastroenterol, 2021, 27(18): 2054-2072.
|
22. |
Park CH, Seo SI, Kim JS, et al. Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: a prospective multicenter study. Sci Rep, 2020, 10(1): 15154.
|
23. |
Pei Z, Bini EJ, Yang L, et al. Bacterial biota in the human distal esophagus. Proc Natl Acad Sci U S A, 2004, 101(12): 4250-4255.
|
24. |
Sun QH, Zhang J, Shi YY, et al. Microbiome changes in the gastric mucosa and gastric juice in different histological stages of Helicobacter pylori-negative gastric cancers. World J Gastroenterol, 2022, 28(3): 365-380.
|
25. |
Guccione C, Yadlapati R, Shah S, et al. Challenges in determining the role of microbiome evolution in Barrett’s esophagus and progression to esophageal adenocarcinoma. Microorganisms, 2021, 9(10): 2003.
|
26. |
柳安琪, 陈汶. 食管微生物与食管相关疾病研究进展. 中华肿瘤杂志, 2019, 41(8): 561-564.
|
27. |
Zou Q, Feng L, Cai X, et al. Esophageal microflora in esophageal diseases. Front Cell Infect Microbiol, 2023, 13: 1145791.
|
28. |
Barona I, Fagundes DS, Gonzalo S, et al. Role of TLR4 and MAPK in the local effect of LPS on intestinal contractility. J Pharm Pharmacol, 2011, 63(5): 657-662.
|
29. |
Lv J, Guo L, Liu JJ, et al. Alteration of the esophageal microbiota in Barrett’s esophagus and esophageal adenocarcinoma. World J Gastroenterol, 2019, 25(18): 2149-2161.
|
30. |
Crouzet L, Gaultier E, Del’Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil, 2013, 25(4): e272-e282.
|
31. |
Dimidi E, Christodoulides S, Scott SM, et al. Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv Nutr, 2017, 8(3): 484-494.
|
32. |
Ye Y, Yin Y, Huh SY, et al. Epidemiology, etiology, and treatment of gastroparesis: real-world evidence from a large US national claims database. Gastroenterology, 2022, 162(1): 109-121.e5.
|
33. |
Hunt RH, Yaghoobi M. The esophageal and gastric microbiome in health and disease. Gastroenterol Clin North Am, 2017, 46(1): 121-141.
|
34. |
Zhang S, Shi D, Li M, et al. The relationship between gastric microbiota and gastric disease. Scand J Gastroenterol, 2019, 54(4): 391-396.
|
35. |
Rajilic-Stojanovic M, Figueiredo C, Smet A, et al. Systematic review: gastric microbiota in health and disease. Aliment Pharmacol Ther, 2020, 51(6): 582-602.
|
36. |
Hao Y, Karaoz U, Yang L, et al. Progressive dysbiosis of human orodigestive microbiota along the sequence of gastroesophageal reflux, Barrett’s esophagus and esophageal adenocarcinoma. Int J Cancer, 2022, 151(10): 1703-1716.
|
37. |
Mladenova I. Clinical relevance of Helicobacter pylori infection. J Clin Med, 2021, 10(16): 3473.
|
38. |
Li M, Sun Y, Yang J, et al. Time trends and other sources of variation in Helicobacter pylori infection in mainland China: a systematic review and meta-analysis. Helicobacter, 2020, 25(5): e12729.
|
39. |
Chen TH, Cheng HT, Yeh CT. Epidemiology changes in peptic ulcer diseases 18 years apart explored from the genetic aspects of Helicobacter pylori. Transl Res, 2021, 232: 115-120.
|
40. |
Miftahussurur M, Doohan D, Nusi IA, et al. Gastroesophageal reflux disease in an area with low Helicobacter pylori infection prevalence. PLoS One, 2018, 13(11): e0205644.
|
41. |
Quach DT, Pham QTT, Tran TLT, et al. Clinical characteristics and risk factors of gastroesophageal reflux disease in Vietnamese patients with upper gastrointestinal symptoms undergoing esophagogastroduodenoscopy. JGH Open, 2021, 5(5): 580-584.
|
42. |
郭薇薇, 陈玲, 缪鑫, 等. 幽门螺杆菌对胃食管反流病影响的 Meta 分析. 胃肠病学和肝病学杂志, 2017, 26(10): 1133-1137.
|
43. |
朱曼, 张倩, 金珍婧. 幽门螺杆菌感染与食管疾病相关性的研究进展. 国际老年医学杂志, 2020, 41(1): 57-61.
|
44. |
Dore MP, Pes GM, Bassotti G, et al. Risk factors for erosive and non-erosive gastroesophageal reflux disease and Barrett’s esophagus in Nothern Sardinia. Scand J Gastroenterol, 2016, 51(11): 1281-1287.
|
45. |
Zhao T, Liu F, Li Y. Effects of Helicobacter pylori eradication on esophageal motility, esophageal acid exposure, and gastroesophageal reflux disease symptoms. Front Cell Infect Microbiol, 2023, 13: 1082620.
|
46. |
徐志洪, 张秀梅, 熊鑫, 等. Barrett 食管与胃肠道微生态研究进展. 华西医学, 2022, 37(10): 1594-1600.
|
47. |
He C, Yang Z, Lu NH. Helicobacter pylori infection and diabetes: is it a myth or fact?. World J Gastroenterol, 2014, 20(16): 4607-4617.
|
48. |
Manes G, Mosca S, Laccetti M, et al. Helicobacter pylori infection, pattern of gastritis, and symptoms in erosive and nonerosive gastroesophageal reflux disease. Scand J Gastroenterol, 1999, 34(7): 658-662.
|
49. |
Yucel O. Interactions between Helicobacter pylori and gastroesophageal reflux disease. Esophagus, 2019, 16(1): 52-62.
|
50. |
Brawner KM, Kumar R, Serrano CA, et al. Helicobacter pylori infection is associated with an altered gastric microbiota in children. Mucosal Immunol, 2017, 10(5): 1169-1177.
|
51. |
Liu B, Dong J, Wang S, et al. Helicobacter pylori causes delayed gastric emptying by decreasing interstitial cells of Cajal. Exp Ther Med, 2021, 22(1): 663.
|
52. |
Niknam R, Lankarani KB, Moghadami M, et al. The association between Helicobacter pylori infection and erosive gastroesophageal reflux disease; a cross-sectional study. BMC Infect Dis, 2022, 22(1): 267.
|
53. |
Mungan Z, Pınarbaşı Şimşek B. Gastroesophageal reflux disease and the relationship with Helicobacter pylori. Turk J Gastroenterol, 2017, 28(Suppl 1): S61-S67.
|
54. |
Zaman C, Osaki T, Hanawa T, et al. Analysis of the microbial ecology between Helicobacter pylori and the gastric microbiota of Mongolian gerbils. J Med Microbiol, 2014, 63(Pt 1): 129-137.
|
55. |
艾合麦提·喀斯木, 买买提·依斯热依力, 克力木·阿布都热依木. 肠道菌群在胃食管反流病发病中的作用及相关性研究进展. 中国医师杂志, 2022, 24(8): 1273-1276.
|
56. |
Singh R, Zogg H, Wei L, et al. Gut microbial dysbiosis in the pathogenesis of gastrointestinal dysmotility and metabolic disorders. J Neurogastroenterol Motil, 2021, 27(1): 19-34.
|
57. |
Yang F, Xie XH, Li X, et al. Analysis of psychological and gut microbiome characteristics in patients with non-erosive reflux disease. Front Psychiatry, 2022, 12: 741049.
|
58. |
王煜姣, 贾庆玲, 李莉, 等. 肠道菌群与胃肠动力关系的研究进展. 世界华人消化杂志, 2021, 29(17): 1020-1025.
|
59. |
Khan Z, Alastal Y, Khan MA, et al. On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis: a systematic review and meta-analysis. Gastroenterol Res Pract, 2018, 2018: 6417526.
|
60. |
Yadlapati R, DeLay K. Proton pump inhibitor-refractory gastroesophageal reflux disease. Med Clin North Am, 2019, 103(1): 15-27.
|
61. |
Kiecka A, Szczepanik M. Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics. Pharmacol Rep, 2023, 75(4): 791-804.
|
62. |
Vereecke L, Elewaut D. Spondyloarthropathies: ruminococcus on the horizon in arthritic disease. Nat Rev Rheumatol, 2017, 13(10): 574-576.
|
63. |
Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut, 2016, 65(5): 740-748.
|
64. |
Haworth JJ, Boyle N, Vales A, et al. The prevalence of intestinal dysbiosis in patients referred for antireflux surgery. Surg Endosc, 2021, 35(12): 7112-7119.
|
65. |
Suri J, Kataria R, Malik Z, et al. Elevated methane levels in small intestinal bacterial overgrowth suggests delayed small bowel and colonic transit. Medicine (Baltimore), 2018, 97(21): e10554.
|